Company Performance Metrics
Petter Björquist: Chief Executive Officer- Jan Holgersson: Co-Founder & Chairman
Verigraft AB is a biotech company that generates personalized tissue-engineered transplants for use in regenerative medicine.
The company’s unique technology platform turns donated allogeneic (“foreign”) tissue into an autologous-like (“personalized”) tissue and thus avoids transplant rejection and the need for life-long immunosuppression.
Donated, allogenic tissue is patient-individualized by a combination of DC (Decellularization) and RC (Reconditioning/Recellularization) processes.
VERIGRAFT’s technology does not require immunosuppression. With this unique, patented and improved alternative to existing treatments, VERIGRAFT strives to deliver a life changing impact to patients and provide major benefits for hospitals, healthcare providers and society – globally.
VERIGRAFT’s personalized tissue-engineered vein (P-TEV) has gone through preclinical development at the company. Safety data from large animals has been generated. Clinical proof-of-concept in humans exists. The product is planned to enter clinical development within 6 months.
